Seoul Technopark announced that it participated in the '2nd International Exhibition on Oriental Medicine and Integrated Medicine (K-MEX 2024)' held at COEX in Seoul on June 22 and operated various programs to promote technology commercialization and corporate support for the Oriental medicine industry.
K-MEX 2024 is an event designed to introduce the latest trends in related industries such as medical devices, pharmaceuticals, and treatment systems in the Korean medicine field and to expand opportunities for cooperation between domestic and foreign companies. In addition to technology exhibitions, various side events such as forums and conferences were held.
As a member of the Korean Medicine Technology Commercialization Committee, Seoul Techno Park participated in this exhibition and carried out practical technology commercialization support activities through technology consultation sessions, committee booth operation, forums, and conferences.
At the 'Future Strategy Forum for Oriental Medicine' held on the first day of the event, Director Jin-Tae Kim of the Strategy Business Office at Seoul Technopark presented on the topic of 'Technology Commercialization Policy Directions that Open the Future of Oriental Medicine,' followed by presentations by industry, academia, research, and government officials from Kyunghee University, Seoul Metropolitan Government Oriental Medical Association, Korea Institute of Science and Technology Information, and Jecheon City on global expansion, demand-based technology development, and regional linkage-based commercialization strategies.
In addition, the Korea Institute of Oriental Medicine and the Korea Invention Promotion Association each introduced their corporate support projects, and private companies and university researchers shared various technology commercialization cases, including ▲ patented technology for manufacturing green tea, ▲ herbal medicine material development system, ▲ multi-lactic acid bacteria technology, ▲ anticancer treatment auxiliary drug, ▲ benign prostatic hyperplasia prevention composition, and ▲ nanopore needle technology.
34 companies participated in the technology consultation held on site and received in-depth consultation from experts in various fields such as technology consulting, intellectual property, and investment attraction. In particular, consultations were actively held on ways to utilize AI in oriental medicine and commercialization strategies based on demand technology, and it was evaluated that support was provided based on actual corporate needs.
Seoul Techno Park selected and distributed '20 promising technologies in Korean medicine' at this expo and provided customized technology information for companies hoping to open innovation. In addition, it operated a booth dedicated to the Korean Medicine Technology Commercialization Committee, introducing technology commercialization activities and linkage plans to about 85 related parties and collecting opinions from the field.
Meanwhile, Seoul Technopark Director Kim Jin-tae received the Seoul Metropolitan Council Chairman's Award in recognition of his contribution to the commercialization of Korean medicine technology.
The Korean Medicine Technology Commercialization Committee is a public-private cooperative body launched in November 2023, and is working towards the commercialization of technology in the Korean medicine and wellness fields, policy improvement, and establishment of an inter-industry collaboration ecosystem.
- See more related articles
You must be logged in to post a comment.